

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 20618-000100
Client Reference No.: N8-79

Assistant Commissioner for Patents
Washington, D.C. 20231

On July 27, 2000

TOWNSEND and TOWNSEND and CREW LLP

By: D. Schaller

Diana M. Schaller

RECEIVED

AUG 03 2000

TECH CENTER 1600/2900

#15

8/9/00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Gregory S. Hageman et al.

Application No.: 09/183,972

Filed: October 29, 1998

For: THERAPEUTICS AND
DIAGNOSTICS FOR OCULAR
ABNORMALITIES

Examiner: S. Turner

Art Unit: 1647

RESPONSE TO RESTRICTION
REQUIREMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action mailed June 27, 2000, please enter and consider the following.

REMARKS

Claims 1-32 are pending in the present application. The Examiner has requested that Applicants elect one group under 35 U.S.C. §121 as follows:

- I. Claims 1-3 and 14-17, drawn to nucleic acids and kit, classified in Class 536; Subclass 23.1;
- II. Claims 4-13, drawn to polypeptides, classified in Class 530; Subclass 300;